Zealand Pharma — November 2021
-
Prøv lige, at læse mit indlæg d. 16 kl. 10:47 og husk nu, at trække vejret dybt inden du læser indlæg, mens du læser det og når du skriver dit svar
-
Jeg er selv lang i ZP og får de bøllebank nu - det er vigtigt at der er plads til differentierede holdninger her. Synes faktisk det kræver en del rygrad af @johnlau at hver gang han skriver noget får han en på sølvhatten. Vi lærer intet ved kun at være bullish - uanset argumenter skal der være plads til alle
-
den del er jeg enig i - så er det ikke en holdning til aktien men personligt - det bør ikke være en del af dette forum
-
(Sanofi q3 2021: Third-quarter Soliqua
sales increased 27.5% to €51 million driven by growth in all three geographic regions. In the Rest of World region, third-quarter Soliqua sales grew 40.0% mainly due to new launches.)Lidt ærgerligt at Zealand frasolgte Soliqua
/Suliqua, men de havde selvfølgelig brug for likviditeten. -
Mon opkøbet vi så fra Novo, kan sætte en bund i nuværende kurs på Zealand. 22 mia. for et lille selskab med en tidlig pipiline, giver i hvert en indikation af potentialet som Zealand bevæger sig i.
-
Dårligere Zegalogue-salg end ventet skuffer ikke Zealand Pharma-direktør
Dårligere Zegalogue-salg end ventet skuffer ikke Zealand Pharma-direktør
Det skaber ikke skuffelse hos Zealand Pharmas adm. direktør, Emmanuel Dulac, at biotekselskabets nødpen Zegalogue har oplevet et dårligere salg end ventet i 2021. Topchefen peger på, at barren har været sat højt fra start.
(medwatch.dk)
-
tak @exitnu
-
Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
Company announcement – No. 70 / 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist,...
GlobeNewswire News Room (www.globenewswire.com)
-
Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosing in humans.
Effects on several biomarkers suggest that clinically relevant exposures of dapiglutide were achieved in the study.
Zealand will be exploring several potential indications in gastrointestinal and metabolic diseases.
-
“We are thrilled with the successful outcome of this Phase 1b clinical trial with dapiglutide and look forward progressing the molecule to the next development phase next year” stated Adam Steensberg, Chief Medical Officer at Zealand Pharma. “Dapiglutide, is a first-in-class peptide drug candidate with dual activity on the GLP1 and GLP2 receptors and thus potential to address several metabolic and gastrointestinal diseases, including short bowel syndrome”
se fx Oncopeptides de seneste dage som iøvrigt er gået fra kurs 3,83 (1. november) til over kurs 12 idag.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind